Sleep deprivation enhances amyloid beta peptide, p-tau and serotonin in the brain: Neuroprotective effects of nanowired delivery of cerebrolysin with monoclonal antibodies to amyloid beta peptide, p-tau and serotonin.
Amyloid beta peptide
Blood–brain barrier
Brain pathology
Nanowired delivery
Phosphorylated-tau
Serotonin
Sleep deprivation
Journal
International review of neurobiology
ISSN: 2162-5514
Titre abrégé: Int Rev Neurobiol
Pays: United States
ID NLM: 0374740
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
4
10
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
ppublish
Résumé
Sleep deprivation is quite frequent in military during combat, intelligence gathering or peacekeeping operations. Even one night of sleep deprivation leads to accumulation of amyloid beta peptide burden that would lead to precipitation of Alzheimer's disease over the years. Thus, efforts are needed to slow down or neutralize accumulation of amyloid beta peptide (AβP) and associated Alzheimer's disease brain pathology including phosphorylated tau (p-tau) within the brain fluid environment. Sleep deprivation also alters serotonin (5-hydroxytryptamine) metabolism in the brain microenvironment and impair upregulation of several neurotrophic factors. Thus, blockade or neutralization of AβP, p-tau and serotonin in sleep deprivation may attenuate brain pathology. In this investigation this hypothesis is examined using nanodelivery of cerebrolysin- a balanced composition of several neurotrophic factors and active peptide fragments together with monoclonal antibodies against AβP, p-tau and serotonin (5-hydroxytryptamine, 5-HT). Our observations suggest that sleep deprivation induced pathophysiology is significantly reduced following nanodelivery of cerebrolysin together with monoclonal antibodies to AβP, p-tau and 5-HT, not reported earlier.
Identifiants
pubmed: 37783554
pii: S0074-7742(23)00033-8
doi: 10.1016/bs.irn.2023.05.009
pii:
doi:
Substances chimiques
Amyloid beta-Peptides
0
Serotonin
333DO1RDJY
cerebrolysin
37KZM6S21G
Neuroprotective Agents
0
Antibodies, Monoclonal
0
Nerve Growth Factors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-162Subventions
Organisme : NIA NIH HHS
ID : R01 AG028679
Pays : United States
Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Conflict of interest There is no conflict of interest between any entity and/or organization mentioned here.